To personalize content, providing social media features and analyzing our traffic, we use cookies. By using the website you agree.

CLINICAL TRIALS

The main objective of CEPOETA is patient-oriented paediatric cancer research.
The research projects are assigned to three areas:


 

  • List of studies in the area of leukaemia and lymphoma

  • List of studies in the area of solid tumours:


    • Title: Recurent Neuroblastoma and Ewing´s sarcoma: Treosulphan based high dose chemotherapy with Autologous PBSC support

    • Acronym: ReNETA

    • EUDRA CT number: 2015-002584-41

    •  

    • Title: Combined anticancer therapy with ex vivo manipulated Dendritic Cells producing interleukin-12 in pediatric, adolescent and young adults with progressive recurrent or primary metastatic malignancies of high risk

    • Acronym: KDO_DC1311

    • EUDRA CT number: 2014-003388-39

  • List of studies in the area of brain tumours and especially rare paediatric cancers 

PUBLICATIONS

20201720

2017

​Fědorová Lenka, Lenka Zdražilová Dubská, Kateřina Pilátová, Peter Múdry, Pavel Mazánek, Zdeněk Pavelka, Eva Hlaváčková, Jaroslav Štěrba, Lucie Flajšarová, Regina Demlová a Dalibor Valík. Immunomonitoring of patients treated with personalized dendritic cell-based vaccine. 2017. ISSN 0923-7534. Annals of Oncology (2017) 28 (suppl_11): xi6-xi29.

Mazánek P. RENETA trial – CEPOETA clinical study. 12th Regional Central-Eastern/South-Eastern European Pediatric Oncohematology Meeting, Abstract book, 28.-30.9.2017

Mudrý P. Autologous dendritic cell vaccine for children with relapsed/refractory and very high risk solid tumors and lymphomas – clinical aspects, 12th Regional Central-Eastern/South-Eastern European Pediatric Oncohematology Meeting, Abstract book, 28.-30.9.2017

Valik D., Autologous dendritic cell vaccine for children with relapsed/refractory and very high risk solid tumors and lymphomas – immunological and biological aspects, 12th Regional Central-Eastern/South-Eastern European Pediatric Oncohematology Meeting, Abstract book, 28.-30.9.2017

Součková L, Štěrba J, Demlová R, Pavelka Z. The Experience with the targeted cancer therapy in paediatric patients – from the perspective of clinical pharmacist, The 13th Congress of the European Association for Clinical Pharmacology and Therapeutics, 24.-27.6.2017, Praha

2016

Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, André N, Slavc I, Berg HV, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J. 2016: Future paradigms for precision oncology. Oncotarget. doi: 10.18632/oncotarget.9488.

 

Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A,Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M. Non-Hodgkin's lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016 Aug 11. pii: haematol.2016.147116.

Eipel O, Hegyi M, Csordás K, Németh K, Luczay A, Török D, Csóka M, Erdélyi D, Kovács G. 2016: Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL. J Pediatr Hematol Oncol, 38(5):334-40.

 

Sági JC, Kutszegi N, Kelemen A, Fodor LE, Gézsi A, Kovács GT, Erdélyi DJ, Szalai C, Semsei AF. 2016: Pharmacogenetics of anthracyclines. Pharmacogenomics,  17:9, 1075-1087.

 

Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. 2016: Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. The Lancet Oncology, 17(3), 332-344.

2015

Řiháček, M, Pilátová, K, Štěrba, J, Pilný, R, Valík, D, 2015: Nové poznatky ve farmakologii methotrexátu – diagnostické možnosti a klinický význam. Klin Onkol, 28(3):163-170.

 

Rihacek, M, Bienertova-Vasku, J, Valik, D, Sterba, J, Pilatova, K, Zdrazilova-Dubska, L. 2015: B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia. BioMed Res Int 2015:792187.

 

Obermannova, R, Dusek, L, Greplova, K, Jarkovsky, J, Sterba, J, Vyzula, R, Demlova, R, Zdrazilova-Dubska, L, Valik, D, 2015: Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study. Neoplasma, 62(6):958-965.

 

Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R. & Zdrazilova-Dubska L. 2015: Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology, 15(1):37.

 

Nunukova A, Neradil J, Skoda J, Jaros J, Hampl A, Sterba J, Veselska R. 2015: Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines. Int J Mol Med, 36(1):65-72. doi: 10.3892/ijmm.2015.2210.

 

Mikulenkova, E, Neradil, J, Zitterbart, K, Sterba, J, & Veselska, R. 2015: Overexpression of the∆ Np73 isoform is associated with centrosome amplification in brain tumor cell lines. Tumor Biology, 36(10), 7483-7491.

 

Neradil J, Pavlasova G, Sramek M, Kyr M, Veselska R, Sterba J. 2015: DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines. Oncol Rep. May;33(5):2169-75. doi: 10.3892/or.2015.3819.

 

Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, Gruenberger T, Shen J, Man K, Trauner M, Yu J, Gao CF & Mikulits W. 2015: Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. International Journal of Cancer, 137(2):385-94.

 

Zdráhalová K, Štěrba J, Domanský J, Blažek B, Ptoszková H, Mihál V, Novák Z, Hak J, Procházková D, Černá Z, Timr P, Jabali Y, Sedláček P, Smíšek P, Zemanová Z, Jarošová M, Houdková A, Mejstříková E, Hrušák O, Zuna J, Janotová I, Trka J, Starý J. 2015: The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial. Cas Lek Cesk, 154(2):79-89.

 

Dousek R, Tuma J, Planka L, Husek K, Sterba J, Penka I. 2015: Inflammatory myofibroblastic tumor of the esophagus in childhood: a case report and a review of the literature. J Pediatr Hematol Oncol, 37(2):e121-4.

 

Ruzsíková A, Součková L, Suk P, Kejdušová M, Šrámek V. et al. 2015: Quantitative analysis of drug losses administered via nasogastric tube - In vitro study. International Journal of Pharmaceutics, 478 (1): 368-371.

Kutszegi N , Semsei AF , Gezsi A , Sagi JC , Nagy V , Csordas K , Jakab Z , Lautner-Csorba O , Gabor KM , Kovacs GT , Erdelyi DJ , Szalai C. 2015: Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity. PloS one, 10(10), e0140136.

 

Gézsi A, Csorba-Lautner O, Erdélyi DJ, Hullám G, Antal P, Kutszegi N, Hegyi M, Csordás K, Kovács G, Szalai C. 2015: In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. The pharmacogenomics journal, 15(3): 241-247.

 

2014

Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM: Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. 2014: Nature, 511 (7510): 428-434.

 

Bencsiková B, Greplová K, Pilátová K, Volejníková Z, Valík D, Klement GL & Zdražilová-Dubská L. 2014: Platelets in the pathogenesis of solid tumors. Casopis Lekaru Ceskych, 153(2):78-85.

 

Demlova R, Mrkvicova M, Sterba J, Bernatikova H, Stary J, Sukova M, Mikuskova A, Chocholova A, Mladosievicova B, Soltysova A, Behulova D, Pilatova K, Zdrazilova-Dubska L. & Valik D. 2014: Augmenting clinical interpretability of thiopurine methyltransferase laboratory evaluation. Oncology, 86 (3): 152-158. ISSN 0030-2414

 

Hamanová M, Zdražilová-Dubská L, Valík D. & Lokaj J., 2014: Natural antibodies against α (1,3) galactosyl epitope in the serum of cancer patients. Epidemiologie, Mikrobiologie, Imunologie, 63 (2): 130-133 ISSN 1210-7913.

 

Obermannova R, Demlová R, Drábová K, Melichárková K, Greplová K, Mrkvicová M, Zdražilová-Dubská L, Vyzula R. & Valík D. 2014: Vitamin D as an important steroid hormone in breast cancer. Klinická Onkologie, 27 (1): 143-149.

 

Pilatova K, Mrkvicova M, Zdrazilova-Dubska L, Obermannova R. & Valik D. 2014: Detection of DPYD*2A allele in dihydropyrimidine dehydrogenase gene: perspective for fluoropyrimidine-treated patients. Folia Mendeliana 2013, 49(2):75-80.

 

Stěrba J, Stěrbová S, Kodytková D, Valík D. & Demlová R. 2014: Clinical evaluation of new drugs against orphan diseases in oncology - the current situation in Europe and in our country. Vnitrni Lekarstvi, 60 (2): 80-5. ISSN 0042-773X.

 

Sedláček P, Múdrý P, Horáková J, Keslová P, Šrámková L, Chrenková V, Hubáček P, Štěrba J. 2014: Guidelines for antifungal prophylaxis, diagnosis and therapy in pediatric hematology and oncology - a review of literature and expert recommendations Klin Mikrobiol Infekc Lek, 20(3):85-91.

 

Demlova R, Melicharkova K, Rehak Z, Kren L, Oslejskova H, Sterba J. 2014: Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. Curr Oncol. Dec;21(6):e790-3. doi: 10.3747/co.21.2147.

 

Chlapek P, Neradil J, Redova M, Zitterbart K, Sterba J, Veselska R. 2014: ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression. Cancer Cell Int 14: Art.No. 51.

 

Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F. 2014: Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience, 8:463. doi: 10.3332/ecancer.2014.463. eCollection 2014

 

Skoda J, Neradil J, Zitterbart K, Sterba J, Veselska R. 2014: EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol Rep, 31: 480-487.

Csordas K, Lautner-Csorba O, F. Semsei A, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai Cs, Kovacs GT. 2014: Associations of novel genetic variations in the folate‐related and ARID5B genes with the pharmacokinetics and toxicity of high‐dose methotrexate in paediatric acute lymphoblastic leukaemia. British journal of haematology, 166(3), 410-420.

 

Ottoffy G, Horvath P, Muth L, Solyom A, Garami M, Kovacs G, Nyári T, Molnár D, Pauler G, Jankovics I. 2014: Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. Pediatric blood & cancer, 61(6), 1013-1016.

 

Bárdi E, Csóka M, Garai I, Szegedi I, Müller J, Györke T, Kajáry K, Nemes K, Kiss Cs, Kovács G. 2014: Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathology & Oncology Research, 20(1), 139-143.

 

2013

Bencsiková B, Greplová K, Pilátová K, Volejníková Z, Valík D, Lakka Klement G. & Zdražilová-Dubská L. 2013: Krevní destičky v patogenezi a léčbě solidních nádorů. Časopis Lékařů Českých, 153(2) ISSN 0008-7335.

 

Doležel J, Čapák I, Valík D, Miklánek D, Macík D, Pacal M, Staník M. & Jarkovský J. 2013: Effect of ureterointestinal anastomosis on renal function and morbidity in intestinal urinary diversion. Scandinavian Journal of Urology, 47(3):225-229. ISSN 2168-1805.

 

Drábová K, Bienertová-Vašků J, Lokaj P, Dubská L, Obermannová R, Greplová K, Demlová R, Valík D. & Stěrba J. 2013: Vitamin D: Its physiology, pathophysiology and significance in etiopathogenesis of malignant diseases. Casopis Lekaru Ceskych, 152(1):20-30. ISSN 0008-7335.

 

Demlova R, Mrkvicova M, Sterba J, Bernatikova H, Stary J, Sukova M, Mikuskova A, Chocholova A, Mladosievicova B, Soltysova A, Behulova D, Pilatova K, Zdrazilova-Dubska L. & Valik D. 2013: Augmenting clinical interpretability of thiopurine methyltransferase laboratory evaluation. Oncology, 86 (3): 152-8.

 

Pilatova K, Mrkvicova M, Zdrazilova-Dubska L, Obermannova R. & Valik D. 2013: Detection of DPYD*2A allele in dihydropyrimidine dehydrogenase gene: perspective for fluoropyrimidine-treated patients. Folia Mendeliana, 49(2): 75-80. ISSN 0085-0748.

 

Springer D, Valík D, Topolčan O, Nekulová M, Zdražilová-Dubská L, Malbohan I, Fuchsová R, Svobodová Š. & Zima T. 2013: Nádorové markery v klinické praxi. Postgraduální medicína, 15(3):40-49.

 

Veselska R, Neradil J, Nekulova M, Dobrucka L, Vojtesek B, Sterba J, Zitterbart K. 2013: Intracellular distribution of the deltaNp73 protein isoform in medulloblastoma cells: a study with newly generated rabbit polyclonal antibodies. Histol Histopathol, 28: 913-924.

 

Bienertova-Vasku J, Mazanek P, Hezova R, Curdova A, Nekvindova J, Kren L, Sterba J, Slaby O. 2013: Extension of microRNA expression pattern associated with high-risk neuroblastoma. Tumour Biol, 34: 2315-2319.

Lautner-Cs O, Gézsil A, Erdélyi DJ, Hullám G, Antal P, F-Semsei Á, Kutszegi N, Kovács G, Falus A, Szalai Cs. 2013: Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by Bayesian relevance and effect size analysis. PloS one, 8(8), e69843.

 

Pállinger É, Kovács G, Horváth Zs, Müller J, Csaba Gy: Changes int he hormone (ACTH, insulin, epinephrine) content of immune cells in children having acute lymphocytic leukemia (ALL). Acta Microbiol Immunol Hun 2013, 60: 423-31.

 

Zombori L, Kovacs G, Csoka M, Derfalvi B. 2013: Rheumatic symptoms in childhood leukemia and lymphoma - a ten-year retrospective study. Ped Rheumat, 11: 20-25.

 

Nemes K, Sebestyén A, Márk Á,  Hajdu M, Kenessey I, Sticz T, Nagy E, Barna G, Váradi Zs, Kovács G, Kopper L, Csóka M. 2013: Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia. PloS one, 8(8): e69843.

 

Csordas K, Hegyi M, Eipel O, Muller J, Erdelyi DJ, Kovacs GT: Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Anticancer Drugs, 2013, 24(2): 189-197.

 

Eipel O, Németh K, Török D, Csordás K, Hegyi M, Ponyi A, Ferenczy A, Erdélyi DJ, Csóka M, Kovács GT. 2013: The glucocorticoid receptor gene polymorphism N363S predispose to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy. International journal of hematology,97(2), 216-222.

 

Haltrich I, Csoka M, Kovacs G, Török D, Alpar D, Ottoffy G, Fekete Gy. 2013: Six cases of rare gene amplifications and multiple copy of fusion gene in childhood acute lymphoblastic leukemia. Pathology & Oncology Research, 19(1), 123-128.